Counter-Strike: Nice Try vs GenOne (BO3) - NODWIN Clutch Series Group Stage

According to the latest prediction market data for the query “Counter-Strike: Nice Try vs GenOne (BO3) - NODWIN Clutch Series Group Stage”, traders have formed a strong consensus.

Currently, Match Winner is dominating the market with an overwhelming 9,995% chance of winning. O/U 2.5 Games follows in second place at 9,995%, while Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5) sits in third with 6,250%. The betting volume for this specific market has already reached $89.6K, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• Match Winner (9,995%): Currently commanding the highest probability, Match Winner is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 9,995¢, signaling a high degree of market conviction. This contract alone has generated $48.0K in volume.

🥈 Tier 2: The Primary Challengers

• O/U 2.5 Games (9,995%): Positioned as the most viable alternative, O/U 2.5 Games maintains a 9,995% chance of resolving true. Its “Buy Yes” shares currently trade at 9,995¢.
• Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5) (6,250%): Sitting in third place with a 6,250% probability, the market shows measured skepticism toward Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5), treating it as an outside wildcard unless momentum shifts.

🥉 Tier 3: The Long-Tail Options (Combining for ~0%)

Beyond the top three choices, a wide field of macro variables and long-shot outcomes are being tracked. While their individual probabilities hover low, they represent crucial hedges for speculative traders:

• Alternative Options: This includes Map 3 Rounds Handicap: Nice Try (-6.5) vs GenOne (+6.5) (5,650%), Map 3 Rounds Handicap: GenOne (-3.5) vs Nice Try (+3.5) (4,350%), and Map 3 Rounds Handicap: Nice Try (-12.5) vs GenOne (+12.5) (4,350%).
• Speculative Volume: Despite low statistical likelihood, certain long-tail contracts like Map 3 Total Rounds: Over/Under 24.5 are still attracting notable interest.

This market refers to the Counter-Strike Round 1 match between Nice Try and GenOne in the NODWIN Clutch Series Group Stage, initially scheduled for November 10, 2026 at 1:00 PM ET.

This market will resolve to "Nice Try" if Nice Try win the match against GenOne.

This market will resolve to "GenOne" if GenOne win the match against Nice Try.

If the match is canceled (not played at all) or ends in a tie, this market will resolve to 50-50.

If the match is postponed, it must be rescheduled to a start time on or before November 24, 2026 at 11:59 PM ET (14 calendar days after the originally scheduled start of November 10, 2026 at 1:00 PM ET). If, by that deadline, the most recently announced rescheduled start time is on or before the deadline, this market resolves based on the result of the match as played. Otherwise, this market resolves 50-50, regardless of whether the match is subsequently played.

If the match begins but is not completed, and one team wins due to the opponent's forfeiture, disqualification, or walkover, this market will resolve to the team who wins.

If the match ends in a forfeit, disqualification, or walkover (team withdraws before the start and the other wins automatically), this market will resolve to 50-50.

The resolution source for this market will be official information from https://hltv.org. However, if https://hltv.org has not published final results within 2 hours after the event’s conclusion, a consensus of credible reporting may be used instead including video evidence.

In cases where a team’s listed name includes minor discrepancies from the resolution source, this market will resolve based on the underlying real-world match rather than exact name matching. Recognizable abbreviations, alternate or erroneous spellings, sponsor tags, affiliate or academy designations, regional identifiers, and minor formatting differences will be treated as referring to the same team, provided the intended team can be clearly and uniquely identified within the relevant competition. If a listed team name has no reasonable connection to any participating team, or if it matches or could reasonably refer to another team in the same competition such that the intended team cannot be unambiguously determined, this market will resolve 50-50.